D-0826-2021 Class II Terminated
FDA drug recall D-0826-2021 was initiated by Glenmark Pharmaceuticals Inc., USA on Aug 27, 2021 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Oct 4, 2023). Affected quantity: a) 216,454 bottles; b) 2166 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 29, 2021
- Initiation Date
- Aug 27, 2021
- Termination Date
- Oct 4, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 216,454 bottles; b) 2166 bottles
Product description
Zonisamide Capsules USP 100 mg Rx Only Manufactured by: Glenmark Pharmaceuticals Inc., USA Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 a) 100 Capsules NDC 68462-130-01; b) 500 Capsules NDC 68462-130-05
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide.
Code information
Lots: a) 29200014 Exp. 02/28/2023; 29200015 Exp. 03/31/2023; 29200016 Exp. 03/31/2023; 29200030 Exp. 05/31/2023; 29200031 Exp. 05/31/2023; 29200032 Exp. 05/31/2023; 29200033 Exp. 06/30/2023; 29200037 Exp. 06/30/2023; 29200038 Exp. 06/30/2023; 29200039 Exp. 07/31/2023; 29200041 Exp. 07/31/2023; 29200042 Exp. 07/31/2023; 29200048 Exp. 08/31/2023; 29200049 Exp. 08/31/2023; 29200050 Exp. 08/31/2023; 29200072 Exp. 11/30/2023; 29200073 Exp. 11/30/2023; 29200074 Exp. 11/30/2023; 29200075 Exp. 11/30/2023; 29200076 Exp. 11/30/2023; b) 29200014 Exp. 02/28/2023; 29200015 Exp. 03/31/2023; 29200016 Exp. 03/31/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0826-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026